Cited by 54Sleep and related disordersAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major Depression

Differential Effects of Nefazodone and Cognitive Behavioral Analysis System of Psychotherapy on Insomnia Associated With Chronic Forms of Major Depression

Thase, Michael E., Rush, A. John, Manber, Rachel, Kornstein, Susan G., Klein, Daniel N., Markowitz, John C., Ninan, Philip T., Friedman, Edward S. +5 more·2002·The Journal of Clinical Psychiatry

Abstract

BACKGROUND: The antidepressant nefazodone and the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) were recently found to have significant, additive effects in a large multicenter study of chronic forms of major depression. As nefazodone-mediated blockade of serotonin-2 receptors may directly relieve insomnia associated with depression, we examined the more specific effects of CBASP and nefazodone, singly and in combination, on sleep disturbances. METHOD: A total of 597 chronically depressed outpatients (DSM-III-R criteria) with at least 1 insomnia symptom were randomly assigned to 12 weeks of treatment with nefazodone (mean final dose = 466 mg/day), CBASP (mean = 16.0 sessions), or the combination (mean dose = 460 mg/day plus a mean of 16.2 CBASP sessions). Continuous and categorical insomnia outcomes, derived from standard clinician- and self-rated assessments, were compared. RESULTS: Patients receiving nefazodone (either alone or in combination with CBASP) obtained significantly more rapid and greater ultimate improvement in insomnia ratings when compared with those treated with CBASP alone. This difference was maximal by the fourth week of therapy and sustained thereafter. Combined treatment did not result in markedly better insomnia scores than treatment with nefazodone alone on most measures, although patients receiving both CBASP and nefazodone were significantly more likely (p < .001) to achieve > or = 50% decrease in insomnia severity. CONCLUSION: Despite comparable antidepressant efficacy, monotherapy with nefazodone or CBASP resulted in markedly different effects on the magnitude and temporal course of insomnia symptoms associated with chronic forms of major depression. Patients receiving the combination of psychotherapy and pharmacotherapy benefited from both the larger and more rapid improvements in insomnia associated with nefazodone therapy and the later-emerging effects of CBASP on the overall depressive syndrome.

Integrity signals

Registry

Crossref · 10.4088/jcp.v63n0605

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cited by

Sorted by citations

Authors
Thase, M. E., Rush, A. J., Manber, R., Kornstein, S. G., Klein, D. N., Markowitz, J. C., Ninan, P. T., Friedman, E. S., Dunner, D. L., Schatzberg, A. F., Borian, F. E., Trivedi, M. H., & Keller, M. B.
Affiliations
University of Pittsburgh (US)
Venue
The Journal of Clinical Psychiatry
Published
2002-06-15
Volume
63
Issue
6
Pages
493-500
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2062188293
Cited by
54
References
0
Citations by year
2025: 1 · 2023: 1 · 2022: 2 · 2020: 1 · 2018: 1 · 2016: 1 · 2015: 5 · 2014: 6 · 2012: 2
FWCI
4.77
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (U01MH061590, MH30915)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
nefazodone, CBASP, insomnia, sleep disorders, antidepressant effects, treatment response
MeSH terms
Adult, Chronic Disease, Combined Modality Therapy, Depressive Disorder, Drug Administration Schedule, Female, Humans, Sleep Initiation and Maintenance Disorders, Male, Personality Inventory, Piperazines, Triazoles, Cognitive Behavioral Therapy, Linear Models, Treatment Outcome, Outcome Assessment, Health Care, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review